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A B S T R A C TObjectives: Productivity losses usually have a considerable impact on
cost-effectiveness estimates while their estimated values are often
relatively uncertain. Therefore, parameters related to these indirect
costs play a role in setting priorities for future research from a societal
perspective. Until now, however, value of information analyses have
usually applied a health care perspective for economic evaluations.
Hence, the effect of productivity losses has rarely been investigated in
such analyses. The aim of the current study therefore was to
investigate the effects of including or excluding productivity costs in
value of information analyses. Methods: Expected value of informa-
tion analysis (EVPI) was performed in cost-effectiveness evaluation of
prevention from both societal and health care perspectives, to give us
the opportunity to compare different perspectives. Priorities for future
research were determined by partial EVPI. The program to prevent
major depression in patients with subthreshold depression wassee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.12.007
inejad@umcg.nl.
ondence to: Leyla Mohseninejad, P.O. Box 30.001, Hopportunistic screening followed by minimal contact psychotherapy.
Results: The EVPI indicated that regardless of perspective, further
research is potentially worthwhile. Partial EVPI results underlined the
importance of productivity losses when a societal perspective was
considered. Furthermore, priority setting for future research differed
according to perspective. Conclusions: The results illustrated that
advise for future research will differ for a health care versus a societal
perspective and hence the value of information analysis should be
adjusted to the perspective that is relevant for the decision makers
involved. The outcomes underlined the need for carefully choosing
the suitable perspective for the decision problem at hand.
Keywords: cost-effectiveness, perspective, productivity costs,
uncertainty, value of information analysis.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Estimates of cost-effectiveness are surrounded by uncertainty.
Reduction of uncertainty is usually costly. A value of information
(VOI) analysis estimates the monetary value of investments that may
be required to eliminate all or part of uncertainty in the evaluations.
Such estimation can support the decision maker in deciding whether
further research is warranted [1]. When further research turns out to
be worthwhile, more detailed VOI analysis can identify the uncer-
tainties that should then become research priorities. VOI for param-
eters estimates the expected VOIs on groups of parameters and
assists the decision maker to decide on those uncertainties. The
concept of VOI analysis [1] was applied in many sectors [2] before it
was introduced in health technology assessment by Claxton [3].
Recently, the number of applications in health care has steadily
grown. A range of studies was published after 2004 [4–13].While the societal perspective is recommended for economic
evaluations in many countries [14], the majority of the previous
studies have applied a health care perspective in analyzing the VOI.
Studies performed in the United Kingdom were just following
national directives in adopting a health care perspective according
to The Guidelines Manual [15]. Also, among the non-UK studies,
however, only a few have taken into account other than direct
health care costs. Some included direct non–health care or some
part of indirect health care costs [10,16]; however, they have ignored
productivity losses. Galani et al. [17] mentioned that cost estimates
included indirect costs, but they did not elaborate further on the
consequences of this for the interpretation of their results. Never-
theless, most guidelines that recommend using a societal perspec-
tive also suggest comparing the results from two perspectives. Such
a comparison has been usually missing from the studies. The
review by Yokota and Thompson [2] highlights that in other sectorsSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
anzeplein 1, 9700 RB Groningen, The Netherlands.
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Hence, to the best of our knowledge, only very few articles have
included productivity losses and if they did, the implications were
not thoroughly discussed. This seems an omission because in
interventions that target chronic diseases with a high prevalence
among patients in their working ages, productivity costs may have
a large impact on cost-effectiveness results. Furthermore, produc-
tivity costs often can be estimated only with large uncertainty.
Information on individuals’ working hours as well as hourly pro-
ductivity may be difficult to ascertain and is not often included in
most clinical trials. Therefore, looking at the impact of the choice of
perspective and inclusion of productivity costs on the outcomes of
a VOI analysis is worthwhile and was the aim of the current study.
A case study was chosen in the field of mental disorders.
Many reports show that mental disorders lead to a reduction in
employee productivity due to absenteeism or impaired function-
ing at work [18]. Depression is one of the major mental disorders
with a high burden of disease [19,20]. Because of work loss,
absenteeism, and presentism, productivity losses resulting from
depression are considerable [21]. A recent study showed that
productivity costs, on average, reflect more than half of the total
costs for the treatment of depressive disorders [22]. In fact, the
majority of costs of depression fall outside the health care sector;
that is, the benefits of preventing depression are not restricted to
the health sector but society as a whole. Accordingly, for many
health care decision makers it will be relevant to consider a
societal perspective in addition to the health care perspective in
evaluating cost-effectiveness in depression prevention. Still, to
date, most economic evaluations of treatments for adults with
depressive disorders have ignored productivity losses [22].
The objective of our study then was to perform a VOI analysis
in cost-effectiveness evaluation of preventing major depression
(MD) in patients with minor depression. We considered both a
societal and a health care perspective and paid attention to the
consequences of different perspectives for policy advice. The
depression case serves as an illustration for many interventions
with large but uncertain effects on productivity costs.Materials and Methods
In a recent study [23], a Markov model based on Vos et al. [24] was
used to evaluate the costs and long-term health benefits of screening
followed by minimal contact psychotherapy (MCP) for depression
prevention. The model was adjusted to allow evaluation of depres-
sion prevention and was adapted to the Dutch setting. The short-
term outcomes of MCP were previously evaluated alongside a
randomized controlled trial [21]. The current article adds an elaborate
VOI analysis and focuses on a comparison between the values of
solving uncertainties for different perspectives. The model was used
to extrapolate the trial outcomes over a 5-year time horizon. Five
years were considered long enough to capture the full effects of the
intervention and still short enough to trust the data on the pop-
ulation and the screening results. The discount rates used were 1.5%
and 4% according to the Dutch Guidelines for pharmacoeconomic
research [25], and monetary outcomes were valued in euros, at the
2008 price level. For clarity reasons, we explain the intervention, the
model, and parameter estimation sources in the following sections.
Intervention
The intervention was opportunistic screening for subthreshold
depression followed by MCP. Full details about the intervention
and its short-term effects compared with no screening have been
published before [26]. In short, opportunistic screening takes
place in three steps: first, people are approached by the assistant
when they are in the waiting room during a regular generalpractitioner visit. Those who are eligible for screening and give
informed consent (participation rate 72.5%) are then screened for
subthreshold depression (screen positive rate 26.6%). In a second
step, screen-positive patients are approached for a further
screening to check whether they meet the inclusion criteria for
subthreshold depression (participation rate 35.7%). Those who
meet all inclusion criteria receive MCP (59.5% of positive screens).
MCP consists of a self-help manual with instructions on
cognitive-behavioral self-help in mood management skills. The
manual contains registration exercises and homework assign-
ments aimed at cognitive restructuring, relaxation, and activity
scheduling to increase pleasant activities.
In the control group, no screening took place. People with
subthreshold depression received care as usual from their gen-
eral practitioner; that is, they were offered treatment on present-
ing themselves with symptoms.
The effects of the intervention were twofold: incidence and
recurrence of MD decreased by 6% [26] and the total annual per-
capita costs decreased by 21% [21].
Patient Population
The intervention targets patients with minor (subthreshold)
depression. Subthreshold depression, which is diagnosed when
a patient has two to four symptoms of MD, has a lifetime
prevalence of 10% [27]. People with minor depression have an
increased risk of developing MD compared with those not meet-
ing the criteria of subthreshold depression [28].
Markov Model
The model distinguishes three main states: subthreshold depres-
sion, MD, and recovered from depression (no MD). Each state is
divided into episodes that last for 4 weeks. After each cycle of 4
weeks, a person has the chance of moving to another state of
disease, or to stay in the same state and start a new episode
within that state. The Markov model is depicted in Figure 1.
The probability of developing MD for people with subthres-
hold depression (the incidence rate) has been assumed to be
independent of the time that persons were in the subthreshold
state, while the probabilities of recovery from MD and relapse
into MD by assumption decreased over the time that was spent in
MD and no-MD states, respectively. Parameters related to costs
and quality-adjusted life-years (QALYs) in the recovered states
are by assumption the same as in the subthreshold states.
Modeling and analyses were all done by means of the R
software environment for statistical computing.
Parameter Estimation
Estimates of relapse and recovery rate as a function of duration
were based on the Dutch NEMESIS study [19], a large population-
based cohort study addressing mental disorders. The time-
dependent probability curves for relapse and recovery rates can
be found in van den Berg et al. [23]. Prevalence of subthreshold
depression, intervention costs, and health care and societal costs
for subthreshold depression were based on trial results [21].
Population parameters and incidence probabilities from subthres-
hold depression to MD were taken from Willemse et al. [26]. Costs
and productivity losses for MD were estimated on the basis of a
review of Dutch studies [29–31]. QALY estimates were based on the
NEMESIS study [19]. Distribution functions were estimated for all
important model parameters. Parameters that were used in the
probabilistic sensitivity analysis are presented in Table 1.
Effects of MCP were conservatively assumed to cease 1 year
after the intervention. That is, after 1 year, persons are assumed
to return to the same risk of developing MD as under care as
usual if still in the subthreshold state.
0-3 weeks
subthreshold
depression  
4-7 weeks
subthreshold
> 1 year subthreshold
depression
0-3 weeks major
depression
4-7 weeks major
depression
> 2 year major
depression
0-3 weeks recovered
from episode
4-7 weeks recovered
from episode
> 2 years recovered
Fig. 1 – The Markov Model.
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The expected value of perfect information (EVPI) was calculated
for a cost-effectiveness range of 0 to 60,000 h/QALY. The global
EVPI was computed as the difference between the expected net
benefit of perfect and current information over a sufficient
number of simulations, and the net benefits of the standard
therapy (no MCP) were assumed to be zero:
EVPI¼Ey max½0,NBðMCP,yÞmax½EyNBðMCP,yÞ,0
Here y represents a list of unknown parameters. Population
EVPIs were then computed by multiplying global EVPIs by the
relevant population sizes. These were based on the prevalence of
subthreshold depression [21].
In addition to this, parameters were grouped to find the
expected value of perfect parameter information (EVPPI) for each
of these groups of parameters. EVPPI or partial EVPI is intended to
inform research priorities, that is, the type of additional evidence
that would be the most valuable to inform the decision. Param-
eters that explained the same concepts were grouped together, as
shown in Table 1. Like the global EVPI, the partial EVPIs were
analyzed for different cost-effectiveness thresholds to see how
they varied for a range of thresholds.
The EVPPI is calculated as the difference between the
expected value of a decision made with perfect information on
a group of parameters and the expected value with current
information on that group of parameters. It reflects the max-
imum value of additional information on the value of this group
of parameters and may serve to help decide whether certain
research to find better information on the parameters is worth its
costs:
EVPPIf¼Ef max½0,Ec9fðMCP,f,cÞmax½EyNBðMCP,yÞ,0
where f is the group of parameters of interest and c
represents the remaining uncertain parameters. To compute
the partial EVPI, first the simulation must be run for parameters
c but with a particular value of f (an inner loop) and then a new
value of f is sampled and the simulation is run again (an outer
loop). This process is repeated until we have sampled sufficiently
from the distribution of f [32].
Number of Simulations
Careful selection of the number of simulations needed in the
inner and outer loops is required to balance off computation time
and precision. The number of sufficient inner and outer loops for
the EVPPIs was computed by using a three-stage algorithm thatestimates the bias and confidence intervals for the outcomes of
EVPPI [33]. Predicted bias and the width of 95% confidence
intervals for different number of inner loops (J) and outer loops
(K) are presented in Table 2 for the health care perspective. The
numbers presented are relative values, indexing the global EVPI
(43,500,000 h) to 100. We chose J ¼ 1000 and K ¼ 100 as the
sufficient numbers for our simulation from both perspectives
because the bias was reasonably low and also the width of the
confidence interval was estimated to be low enough at 3% of the
global EVPI.Results
Estimates of effects and costs per intervention together with
incremental effects and costs are shown in Table 3. From a health
care perspective, the incremental cost-effectiveness ratio of MCP
compared with the standard therapy (no MCP) is about 1100
h/QALY. From a societal perspective, the intervention is cost
saving [23].
We illustrate our results showing outcomes for two different
perspectives in single pictures/graphs with the cost-effectiveness
threshold on the horizontal axis, allowing a comparison of the
societal and health care perspectives.EVPI
Figure 2 depicts the cost-effectiveness acceptability curves
(CEACs) together with results of EVPI from a societal perspective
and a health care perspective. CEACs were also presented by van
den Berg et al. [23], but are repeated here to support explanation
of the EVPI.
From a health care perspective, at low cost-effectiveness
thresholds, prevention by using MCP is not cost-effective. The
value of perfect information is relatively low because the decision
not to implement MCP is relatively certain to be the best decision.
The EVPI rises to a maximum of 57 million euros at a threshold
value of about 1100 h/QALY, which is equal to the mean cost-
effectiveness of the intervention from a health care perspective.
For larger thresholds, the probability that the MCP is cost-
effective increases and the EVPI decreases with the threshold
rising. At a threshold surpassing the mean incremental cost-
effectiveness ratio, we expect the intervention to be cost-
effective and the decision is less likely to be changed by further
information. With increasing cost-effectiveness thresholds, the
value paid for each additional QALY increases. Hence, at high
Table 1 – Distributions of the parameters of intervention used in PSA (the EVPPI group indicates how the parameters were grouped for the partial
value of information analysis).
No MCP MCP EVPPI group
Distribution Mean (SE) Distribution Mean (SE)
Screening
process
Fraction of the target population that
agrees to be screened [26]
Beta distribution
(a ¼ 3826; b ¼ 1452)
0.725 (0.006) Population
Fraction of screened included for
diagnostic interview [26]
Beta distribution
(a ¼ 364; b ¼ 3463)
0.095 (0.005) Population
Fraction of interviewed included in
intervention [26]
Beta distribution
(a ¼ 217; b ¼ 148)
0.595 (0.026) Population
Subthreshold
states
Incidence probabilities from subthreshold
to major depression [26]
Beta distribution (a ¼ 21;
b ¼ 90)
0.016 (0.003) Beta distribution
(a ¼ 14; b ¼ 95)
0.011 (0.003) Incidence rate
Health care costs [21] Gamma distribution
(shape ¼ 15; scale ¼ 108)
1627 (419) Gamma distribution
(shape ¼ 31; scale ¼ 55)
1687 (305) Health care costs
subthreshold
Productivity loss [21] Gamma distribution
(shape ¼ 22; scale ¼ 300)
6481 (1393) Gamma distribution
(shape ¼ 8; scale ¼ 576)
4638 (1634) Productivity loss
Direct nonmedical costs [21] Gamma distribution
(shape ¼ 43; scale ¼ 12)
507 (77) Gamma distribution
(shape ¼ 56; scale ¼ 8)
441 (59) –
Quality of life [19] Uniform distribution (0.81–1) 0.91 (0.05) Same as no MCP QALYs
Major
depression
states
Health care costs [29–31] Gamma distribution
(shape ¼ 15; scale ¼ 152)
2280 (589) Same as no MCP Health care costs
major depression
Productivity loss [29–31] Gamma distribution
(shape ¼ 8; scale ¼ 27)
216 (76) Same as no MCP Productivity loss
EVPPI, expected value of perfect parameter information; MCP, minimal contact psychotherapy; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life-years; SE, standard error.
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Table 2 – Predicted bias and 95% CI for Monte Carlo partial EVPI estimate [33], EVPI indexed to 100.
J ¼ 10 J ¼ 100 J ¼ 500 J ¼ 1,000 J ¼ 5,000 J ¼ 10,000
Bias (independent of K) 7.62 0.54 0.21 0.05 0.03 0.09
95% CI
K ¼ 10 303.74 56.63 24.82 17.95 11.1 5.2
K ¼ 100 35.94 10.14 4.5 2.94 1.51 0.83
K ¼ 500 7.16 2.02 0.9 0.59 0.3 0.17
K ¼ 1,000 3.58 1.01 0.45 0.29 0.15 0.08
K ¼ 5,000 0.72 0.2 0.1 0.06 0.03 0.02
K ¼ 10,000 0.35 0.1 0.05 0.03 0.01 0.01
CI, confidence interval; EVPI, expected value of perfect information.
Table 3 – Estimates of effects and costs per inter-
vention and incremental effects and costs.
QALYs
(1,000)
Health care
costs
(1,000,000)
Total costs
(1,000,000)
No MCP 1,158 2,911 11,612
MCP 1,170 2,924 11,240
Incremental 12 13 372
MCP, minimal contact psychotherapy; QALY, quality-adjusted life-
year.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 9 0 – 4 9 7494values of the threshold, the global EVPI rises again because of an
increased investment risk.
In contrast, from a societal perspective, the intervention is
cost saving on average and the probability of a correct decision is
always increasing as the threshold gets higher; hence, the global
EVPI is always decreasing. We expect, however, that at very high
thresholds (which are not shown in these graphs), the EVPI starts
to rise, because high threshold values mean that a wrong
decision is extremely costly.
It is apparent that the VOI is mostly higher from a societal
perspective than from a health care perspective. Toward the right
end of the willingness-to-pay scale, however, the VOI from the
health care perspective rises above the levels of the EVPI from a
societal perspective. This can be explained by having a look at the
CEAC: it shows that the probability of making an incorrect
decision remains higher for the health care perspective. Compar-
isons, however, of the VOI for different perspectives might
require different willingness-to-pay thresholds. The amount that
the decision maker is willing to pay per additional QALY would
most likely change when different perspectives are considered.
Therefore, to reach the best comparison, the values of the
thresholds relevant for the decision makers should be known.
For instance, if the threshold for evaluating MCP from a health
care perspective is 20,000 h/QALY and the threshold for the same
intervention from a societal perspective is 40,000 h/QALY, then
the CEACs and EVPIs must be compared on two different points
of 20,000 and 40,000 h/QALY on the x-axis. The vertical lines in
Figure 2 show the comparison considering these hypothetical
threshold values. We will come back to this point in discussion.Fig. 2 – (a) Global expected value of perfect information
(EVPI) curves; and (b) Cost effectives acceptability curves.Partial EVPI
The EVPI for separate parameters groups from the societal
perspective is illustrated in Figure 3. Results indicated that when
the societal perspective is considered, the productivity loss was
the most important source of uncertainty at any threshold. The
effect of productivity loss, however, was more important for lowthresholds than for higher ones. The next important parameter
group was health care costs (including both subthreshold depres-
sion and MD), which became more prominent at higher thresh-
olds. The third and fourth priorities would be given to parameters
related to QALYs and the incidence rate. Other parameters, such
Fig. 3 – Partial EVPI curves considering a societal
perspective. EVPI, expected value of perfect information;
QALY, quality-adjusted life-year.
Fig. 4 – Partial EVPI curves considering a health-care
perspective. EVPI, expected value of perfect information.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 9 0 – 4 9 7 495as population and recovery-relapse rates, were not significantly
affecting the VOI, indicating that they would have a low priority
in further research.
Results of the partial EVPI from a health care perspective are
shown in Figure 4.
The partial EVPI graph indicated that the most important
sources of uncertainty were health care costs. Because health
care costs had such a clear effect on the uncertainty of the
problem, they have been subdivided into two groups of param-
eters: health care costs in subthreshold depression and in MD. At
very low thresholds, costs of MD were more important than at
high thresholds. The health care costs of MD had an almost
negligible expected VOI at thresholds above 5000 h/QALY. The
incidence rate also had a considerable impact at low thresholds,
but a low impact at high thresholds. Results showed that the
most important priorities in future research were those related tothe health care costs of subthreshold depression. The population
that will finally receive the MCP also became an important
parameter at high willingness-to-pay thresholds. This parameter
is determined by the fraction of the target population that agrees
to be screened, fraction of screened included for diagnostic
interview, and fraction of interviewed included in intervention.
Other parameters, related to QALYs, recovery rates, and relapse
rates, were of very little importance in the health care
perspective.Discussion
This article examined how the VOI would change for different
perspectives. The case study was the decision whether to use
opportunistic screening in combination with MCP to reduce the
incidence of MD. For depression, absence from work and the
associated productivity costs represent an important part of the
burden of disease. For this reason, results were evaluated both
from a societal perspective and from a health care perspective.
We found that regardless of the perspective, parameters related
to costs had the largest EVPIs; that is, resolving their uncertainty
would be most valuable for this case study. From a societal
perspective, however, productivity costs got priority, while these
were by their very nature ignored from a health care perspective.
The current case study could be illustrative for many other
mental disorders: often productivity costs represent a relatively
large part of the disease burden, and they are also often relatively
uncertain due to a lack of data. It is obvious that when the
societal perspective is relevant for the decision maker, a VOI from
a health care perspective may lead to erroneous priorities for
further research, especially in the presence of large and uncertain
productivity costs.
Comparing the cost-effectiveness results from a societal
perspective to a health care perspective as required by most
guidelines recommending a societal perspective indicates that
including societal costs in the analyses may significantly affect
the outcomes and even change the decisions. The changes occur
regarding not only the acceptability of the intervention but also
priorities for further research and VOI. According to the cost-
effectiveness acceptability curves (Fig. 2), for very low
willingness-to-pay thresholds, from a health care perspective
rejecting the intervention seems to be the most reasonable
decision. From a societal perspective, however, for low thresh-
olds, accepting the intervention has a fair chance of being cost-
effective.
To have an estimation of the EVPI, we look at the graphs at the
unofficial Dutch thresholds for preventive interventions of 20,000
h/QALY [34]. This threshold was first mentioned in a health care
perspective setting [35]. It has also been used, however, for
analyses in a societal perspective [34]. At the threshold of
20,000 h/QALY, the global EVPIs had a value of about 42 and 32
million euros from societal and health care perspectives, respec-
tively, both indicating that it would be worthwhile to gather more
information.
Hence, using an invalid perspective could lead to unrealistic
importance attached to additional research, depending on the
actual threshold value. As mentioned in the ‘‘Results’’ section,
however, considering the same threshold for both perspectives is
not very practical. In real-world decisions, threshold values
change on the basis of the perspective chosen. From a societal
perspective, threshold values should reflect the consumption
value of health, while from a health care perspective they would
reflect the marginal value of health provided for by a publicly
financed health care system, which are not necessarily the same.
Opinions differ, however, on this issue [14,36]. Meanwhile, it is
not clear how large the difference between the two thresholds
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 9 0 – 4 9 7496should be. In applications, similar threshold values are some-
times mentioned in studies applying a societal perspective as
well as studies using a health care perspective. For instance,
as mentioned before, the unofficial Dutch threshold of
20,000 h/QALY has been used in both health care and societal
perspectives, indicating the difficulties in understanding the
relationship between perspective and threshold in many decision
contexts.
We chose to illustrate our results in graphs with a single
threshold on the x-axis. If the actual thresholds were larger from
a societal perspective (following the reasoning in Claxton et al.
[14]), then a figure that compares both perspectives should use
two different scales on the x-axis, effectively shifting the societal
perspective graph to the left. This implies that the differences
between the societal and health care perspectives in the value of
the global EVPI decrease. It is obvious that the only way to reach a
precise comparison between the VOI from the two perspectives is
to know the exact willingness-to-pay threshold considering each
perspective.
Using a health care perspective, VOI analysis informs decision
makers about allocating funding for actual interventions and
research that basically can be considered as originating from the
same health care budget. All costs and savings hence refer to the
same budget and decision maker, even if in reality earmarking
and separate budgets will be present. Using a societal perspec-
tive, however, this may no longer hold. For instance, savings in
productivity costs will accrue to employers, not to health care
decision makers. In recent years, this has led to discussions on
how the costs of interventions and research must be sponsored
when a societal perspective is considered. Debates are mostly
focused on public health interventions, in which the impacts are
often wide-ranging. Costs and benefits associated with an inter-
vention aiming at public health, such as the depression preven-
tion case, will fall on many sectors within the society [37]. Some
authors just assume that when a societal perspective is taken,
the society pays for health care interventions through a single
payer system and also pays for research projects for reducing
uncertainties through government or private donation-based
agencies [38]. Weatherly et al. [37] reviewed a number of
approaches that have been suggested to account for the impact
of interventions across different sectors. For instance, Claxton
et al. [39] introduce a multisectoral societal decision-making
approach to evaluate costs and benefits that fall on different
sectors of the economy. Smith et al. [40] also demonstrate the
value of using a macroeconomic approach to modeling a major
health problem, using the context of antimicrobial resistance and
applying general equilibrium analysis. Following Willan and
Pinto [38], it seems valid to argue that a societal perspective
implies that resources can—in principle—be transferred from
one part of the economy to the other and the extended Pareto
criterion may be applied to decide whether an intervention or
additional research is worthwhile. Hence, in the presence of
uncertainty, VOI analysis will inform whether additional research
is potentially worthwhile from a societal point of view to support
better future decision making, independent of who is going to
pay or gain from this research.
To conclude, our results underlined the need for carefully
choosing the relevant perspective for the decision problem at
hand, also in VOI analyses, to avoid erroneous choice of research
priorities.
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